AlphaTON Capital Corp — Director's Dealing 2018

Jan 25, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Biohaven Pharmaceutical Holding Co Ltd. (BHVN)
CIK: 0001689813
Period of Report: 2018-01-19

Reporting Person: PORTAGE BIOTECH INC. (former 10% owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-01-19	Common Stock	S	35119	$30.0348	Disposed	78771	Direct
2018-01-23	Common Stock	S	24277	$331520	Disposed	54494	Direct

Footnotes

F1: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2017.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 - $30.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 - $33.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

F4: The reduction in shares reflects the sale of shares reported upon and the dividend distribution of 6,102,729 shares of common stock completed on January 16, 2018.